- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Utilization Management Strategies for Appropriate Treatment
A discussion on utilization management strategies for optimizing the treatment for patients with heart failure.
EP: 1.Heart Failure Clinical and Economic Burden
EP: 2.The Progressive Nature of Heart Failure
EP: 3.Link Between LVEF, NT-ProBNP and Cardiac Remodeling
EP: 4.Improved Understanding of Heart Failure
EP: 5.Treatment Goals for Patients With Heart Failure
EP: 6.The HFrEF Standard of Care
EP: 7.Heart Failure Management Unmet Needs
EP: 8.Utilization Management Strategies for Appropriate Treatment
EP: 9.Challenges in the Management of HFpEF
EP: 10.Differences in Standard of Care: HFpEF vs HFrEF
EP: 11.Ensuring Timely and Appropriate Access to Therapy
EP: 12.Differences in Economic Burden: HFpEF and HFrEF
EP: 13.PROVE-HF Trial Overview
EP: 14.PARAGON-HF Trial Overview
EP: 15.Recent Findings from the PARALLAX Study
EP: 16.Promising Findings From the TOPCAT Study
EP: 17.Differences in Leading Treatments for Heart Failure
EP: 18.When to Add an SGLT2 Inhibitor to Treatment Regimen
EP: 19.Heart Failure Sites of Care
EP: 20.How Approved Agents Will Change the Standard of Care
EP: 21.Heart Failure Management During COVID-19
Jaime Murillo, MD: The beauty and challenge at the same time in heart failure is that we have 4, some people count 5, different lines of therapy for heart failure. The reality is that they all work. Where we have an opportunity is in trying to define the groups that benefit most from X therapy.
We have beta-blockers, we have spironolactone and the like, we have all these ACE inhibitors, we have ARBs, we have SGLT2 therapy. Unfortunately, because of the nature of the trials, there is no way for us to tell who benefits from what. That’s the reality. Most people will start therapies with, “What is the affordable medication I can start with?” That person may benefit from a different approach, but we don’t know that yet. In our health plan [at United Health Care], what we have done is that we essentially opened the approach with few exceptions. Then we will very rarely use a step therapy, as we call it, before people have access to medications for heart failure. I suspect that that landscape will evolve as we learn more about which patients benefit the best or better from a specific line of therapy for heart failure.
Racial, Ethnic Disparities May Impact Age Differences at First Heart Failure Hospitalization
September 4th 2025Social determinants of health were associated with a younger age of first hospitalization for heart failure in Black and Hispanic patients when compared with Asian and White patients.
Read More
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Patients With HFpEF May Benefit From Accelerated Cardiac Pacing
August 28th 2025In an observational extension of the myPACE clinical trial, researchers found that a personalized accelerated pacing in patients with heart failure with preserved ejection fraction (HFpEF) and a preexisting physiological pacer saw a slower trend in adverse cardiac events and overall improved health status.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Finerenone Demonstrates Safety and Efficacy in Heart Failure When Combined With Diuretics
August 13th 2025Clinical trial results establish the safety and efficacy of finerenone to help preserve potassium levels and reduce sodium in patients on diuretics with heart failure and mildly reduced ejection fraction or preserved ejection fraction.
Read More
Genetics, Comorbidities Associated With Cardiomyopathy and Atrial Fibrillation
August 13th 2025The cause of dilated cardiomyopathy (DCM) can be associated with the presence of the TTN gene combined with preexisting comorbidities like atrial fibrillation, which increase the odds of developing DCM.
Read More
